Adocia Adocia
  • Adocia
    • About
    • History
    • Management
    • Board of directors
    • Advisory board
  • Products and platforms
    • Pipeline
    • Technology Platforms
  • Careers
    • The « Adocians »
    • HR policy
    • Work environment
    • Join us
  • Partnering
  • Investors
  • Media
  • Contact
    • Contact us
    • Map and accessibility
  • Investors
    • Regulated information
    • Stock information
    • Corporate governance
    • General meeting
  • Media
    • Press releases
    • Media
  • EN
    • FR

Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Previous article“Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
Next article“Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)” (Poster 1001), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
Adocia
  • Adocia
  • Products and platforms
  • Careers
  • Partnering
  • Investors
  • Media
  • Contact
Contact us
+33(0)4 72 610 610 contact@adocia.com

Adocia
115 Avenue Lacassagne
69003 Lyon, France

2026 © Adocia

  • Site plan
  • Legal notice
  • Privacy policy and cookies policy
  • Managing cookies
Website by Un Brin de CampagneUn Brin de Campagne